Novo Nordisk has announced plans to invest 2.9 billion Danish kroner (approximately $400 thousand) into the construction of a new quality control laboratory  in Denmark.

The facility, which will cover 53,000 square feet, is intended to expand the company’s manufacturing capacity to meet growing global demand. The laboratory will serve as a central hub for quality control operations in Denmark, consolidating existing locations. It is designed to comply with the demands of current and future Good Manufacturing Practice (GMP) and will be able to cater not only to known demand but also provide the flexibility to support future capacity expansions. The facility will use new technologies and digitalisation to automate processes and further strengthen quality control processes.

Construction has been initiated and will be finalised in 2027.